Table 1

Baseline features and results

	All patient eyes	Stratified by anti-VEGF medication			Stratified by baseline VA
		Aflibercept	Bevacizumab	Ranibizumab	20/40 or better	20/40 to 20/70	20/70 to 20/200	20/200 or worse
Patient eyes
n	28 658	6459	15 273	6926	10 585	9633	5939	2469
%	100	23	53	24	37	34	21	9
Gender (%)
Male	53	54	52	54	55	53	51	49
Female	47	46	48	46	45	47	49	51
Mean age (years)	62.1	63.1	61.1	63.4	60.9	63.3	63	61.2
Mean number of injections in 1 year	6.4	6.3	6.3	6.7	6.1	6.6	6.6	6.1
Mean VA (letters)
Baseline VA	59.2	60.3	57.9	61	75.6	63.5	47.4	1.2
Change at 1 year	+4.2	+4.3	+4.5	+3.4	−2.2	+2.0	+6.7	+34.2
Final VA	63.4	64.6	62.4	64.4	73.4	65.5	54.1	35.4
P value	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
95% CI	4.0 to 4.5	3.9 to 4.8	4.2 to 4.9	3.0 to 3.9	−2.7 to −2.1	1.7 to 2.3	6.2 to 7.3	33.4 to 36.8